Last $1.73 USD
Change Today 0.00 / 0.00%
Volume 925.5K
STEM On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 4:30 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

stemcells inc (STEM) Snapshot

Open
$1.73
Previous Close
$1.73
Day High
$1.75
Day Low
$1.70
52 Week High
07/3/14 - $2.43
52 Week Low
04/15/14 - $1.15
Market Cap
117.8M
Average Volume 10 Days
2.0M
EPS TTM
$-0.64
Shares Outstanding
68.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STEMCELLS INC (STEM)

stemcells inc (STEM) Related Businessweek News

No Related Businessweek News Found

stemcells inc (STEM) Details

StemCells, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of stem cell therapeutics, and related tools and technologies for stem cell-based research and drug discovery and development. It develops HuCNS-SC cells that completed Phase I clinical trial in pelizaeus-merzbacher disease, a fatal myelination disorder in brain; completed a Phase I clinical trial in infantile and late infantile neuronal ceroid lipofuscinosis, which is a neurodegenerative disorder of the brain; and conducting preclinical studies in alzheimer’s disease. The company is also developing HuCNS-SC cells that are in Phase I/II clinical trial for the treatment of chronic spinal cord injury, as well as for dry age-related macular degeneration. In addition, it is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company markets a range of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. Its proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. The company serves researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.

58 Employees
Last Reported Date: 03/13/14
Founded in 1988

stemcells inc (STEM) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $835.8K
Executive Vice President of Scientific & Stra...
Total Annual Compensation: $457.3K
General Counsel and Secretary
Total Annual Compensation: $377.0K
Compensation as of Fiscal Year 2013.

stemcells inc (STEM) Key Developments

StemCells, Inc. Appoints Alan Trounson to Board of Directors

StemCells Inc. announced the appointment of Alan Trounson, Ph.D. to its Board of Directors. Dr. Trounson most recently served as President of The California Institute of Regenerative Medicine (CIRM).

StemCells Inc. - Special Call

To discuss the interim results from the Phase I/II clinical trial of HuCNS-SC cells in dry AMD

StemCells, Inc. Interim Results Show Improvement in Visual Function and Slowing of Disease Progression in Phase I/II Dry Amd Trial

StemCells Inc. reported positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SC(R) human neural stem cell platform in dry age-related macular degeneration at the 12th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada. Interim trial results show a 65% reduction in the rate of geographic atrophy (GA) in the study eye when compared to the expected natural history of the disease as well as a 70% reduction in the rate of GA when compared to the control eye. GA is the progressive loss of two important retinal tissue layers, the photoreceptors and the retinal pigmented epithelium. This degeneration is the cause of vision loss in dry AMD. Interim results also indicate improvements in visual function, as measured by the ability to distinguish shades of light versus dark, also referred to as "contrast sensitivity." Contrast sensitivity was improved in four of the seven patients and remained stable in the other three patients. The interim analysis is based on a minimum follow up of at least 6 months and demonstrates a favorable safety profile for administration of the HuCNS-SC cells into the sub-retinal space of the study eye.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STEM:US $1.73 USD 0.00

STEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aastrom Biosciences Inc $3.34 USD +0.01
Athersys Inc $1.69 USD +0.03
Bioheart Inc $0.03 USD +0.0032
BioTime Inc $2.61 USD -0.14
Cytori Therapeutics Inc $2.16 USD -0.04
View Industry Companies
 

Industry Analysis

STEM

Industry Average

Valuation STEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 76.1x
Price/Book 12.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 59.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMCELLS INC, please visit www.stemcellsinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.